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was also evident in nuclei with strong synaptic connections 
(efferent and afferent) to the site of infusion, indicating 
that spread was dependent on synaptic connectivity rather 
than spatial proximity. This notion was further supported 
by infusion-related tau pathology in white matter tracts that 
interconnect these regions. The rapid and robust propaga-
tion of tau pathology in this model will be valuable for both 
basic research and the drug discovery process.
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Introduction
Alzheimer’s disease (AD) is a neurodegenerative disorder 
that is characterised by extracellular amyloid plaques and 
intracellular neurofibrillary tangles (NFTs) [20], with the 
latter being composed of microtubule-associated protein 
tau [6]. Tau normally stabilises microtubules and promotes 
their assembly [15, 48], but in NFTs it is hyperphospho-
rylated and forms insoluble filamentous aggregates [22]. 
Abnormal tau accumulation is also characteristic of other 
neurodegenerative diseases, including progressive supra-
nuclear palsy (PSP), corticobasal degeneration (CBD) and 
Pick’s disease (PiD), which are collectively termed tauopa-
thies [31]. Pathogenic mutations in the tau gene (MAPT) 
give rise to frontotemporal lobar degeneration (FTlD-Tau), 
indicating that tau dysfunction is sufficient to cause neuro-
degeneration and dementia [25, 38, 44]. In AD the sever-
ity of NFT pathology correlates with cognitive decline, 
further supporting the link between tau pathology, func-
tional impairment and neurodegeneration [47]. These stud-
ies highlight abnormal tau as a potential therapeutic target 
and emphasise the need for understanding the molecular 
Abstract Intracellular inclusions composed of hyper-
phosphorylated filamentous tau are a hallmark of Alz-
heimer’s disease, progressive supranuclear palsy, Pick’s 
disease and other sporadic neurodegenerative tauopa-
thies. recent in vitro and in vivo studies have shown that 
tau aggregates do not only seed further tau aggregation 
within neurons, but can also spread to neighbouring cells 
and functionally connected brain regions. This process is 
referred to as ‘tau propagation’ and may explain the stereo-
typic progression of tau pathology in the brains of Alzhei-
mer’s disease patients. Here, we describe a novel in vivo 
model of tau propagation using human P301S tau trans-
genic mice infused unilaterally with brain extract contain-
ing tau aggregates. Infusion-related neurofibrillary tangle 
pathology was first observed 2 weeks post-infusion and 
increased in a stereotypic, time-dependent manner. Con-
tralateral and anterior/posterior spread of tau pathology 
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mechanism(s) of tau-associated neurodegeneration, which 
will be critical for developing novel therapeutic strategies.
NFTs appear in a progressive and stereotypical fash-
ion, which enabled Braak and Braak to stage their sever-
ity and distribution [5]: stages I-II are thought to represent 
prodromal AD, with NFTs largely confined to the entorhi-
nal cortex; stages III-IV are associated with mild cognitive 
impairment and hippocampal involvement, whereas stages 
V-VI represent clinically apparent AD and NFTs extending 
into the neocortex [5]. Only recently, this apparent induc-
tion and spread of tau pathology has been demonstrated 
experimentally.
Clavaguera et al. [9] showed that abnormally phospho-
rylated, filamentous tau derived from the brains of human 
P301S tau transgenic mice was sufficient to induce the 
formation of silver-positive tau inclusions in AlZ17 mice 
that overexpress wild-type human tau, but do not develop 
tau inclusions. They also showed that tau pathology devel-
oped progressively and spread from the sites of infusion 
to neighbouring brain regions. This was consistent with in 
vitro data showing that tau aggregates can be internalised 
by cultured cells, resulting in the fibrillisation of expressed 
tau [17]. These studies have suggested that tau aggregates, 
like extracellular amyloids [19, 43], can recruit monomeric 
tau into fibrillar aggregates that spread to neighbouring 
brain regions through an as yet unknown mechanism. This 
process is referred to as ‘tau propagation’ and has been pro-
posed to explain the stereotypic progression of NFT pathol-
ogy [16, 42]. There is also a growing body of evidence to 
suggest that tau pathology may spread via synaptically con-
nected networks. Using bigenic mice, which overexpressed 
human P301l tau apparently specifically in layer II neurons 
of the entorhinal cortex, tau pathology was shown to spread 
from this region to hippocampal neurons in a progressive 
fashion, despite there being no detectable transgene expres-
sion in the hippocampus [12, 33]. Although these experi-
mental models help to elucidate the mechanism(s) of tau 
propagation, there are limitations from the perspective of 
developing novel tau-based therapies. The AlZ17 propa-
gation model takes 15 months before robust tau pathol-
ogy is evident, with no apparent neurodegeneration [9]. 
The region-specific expression models take 18 months to 
develop robust propagation-related pathology [12, 33] and 
the possibility of low human mutant tau expression being 
responsible for the apparent synaptic spread cannot be 
ruled out [42].
In the present study, we used the human P301S tau trans-
genic line to develop an accelerated model of tau propaga-
tion and to study the relationship between tau spread and 
synaptic connectivity. The P301S tau transgenic model 
overexpresses the 0N4r isoform of human tau containing 
the P301S mutation under the murine thy1 promoter [1]. 
Homozygous mice from this line develop a severe para-
paresis, robust neuronal tau pathology (hyperphospho-
rylated and fibrillar) and extensive neurodegeneration by 
5–6 months of age. Although some tau pathology has been 
reported in the forebrain of P301S tau mice, the brunt of 
pathology is present in brainstem and spinal cord [1].
Materials and methods
Transgenic mice
The generation of homozygous P301S tau transgenic mice 
has been reported previously [1]. Mice (line 2541) were 
bred on a mixed C57Bl/6JxCBA/ca background. Wild-
type (WT) mice on a C57/Bl/6J background were obtained 
from Charles river (Margate, UK).
Preparation of brain extracts and infusion procedure
All procedures were performed in accordance with the 
approved eli lilly ethical review board and UK Home 
Office guidelines. Brain extracts were prepared from end-
stage (5–5.5 months) P301S tau mice and age-matched WT 
controls, as previously described [9]. In brief, mice were 
killed via dislocation of the neck and decapitation; brain 
stems were rapidly dissected on wet ice and snap frozen on 
dry ice. Frozen brainstems from five mice were combined 
and homogenised at 10 % (w/v) in sterile phosphate-buff-
ered saline (PBS), briefly sonicated (Branson 450, output 
2, 5 × 0.9 s) and centrifuged at 3,000g at 4 °C for 5 min. 
The supernatant was stored at −80 °C until use; see sup-
plementary material for concentration of protein and tau in 
brain extracts.
Female P301S tau mice were randomly assigned to three 
groups and five time points, as summarised in Table 1. 
Two-month-old P301S tau mice were anaesthetised with 
isoflurane (2–3 % in O2, 2 l/min) following sedation with 
Table 1  Treatment groups, time points and sample sizes
Mice were unilaterally infused with P301S brain extract (P301S Be), 
sterile phosphate-buffered saline (PBS) or wild-type brain extract 
(WTBe), and were aged to pre-defined time points
PI post-infusion
a
 5 mice used for biochemistry
Time (PI) Age (months) Treatment groups (n)
P301SBe PBS WTBe
1 day 2 5 5 –
2 weeks 2.5 5 – –
1 month 3 5 5 –
2 months 4 5 – –
2.5 months 4.5 10a 5 8
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medetomidine (Domitor© 1 mg/kg s.c.). Once deeply 
anaesthetised, they were placed in a stereotaxic frame and 
a heating blanket with a rectal probe used to maintain body 
temperature. Maintenance anaesthesia was given at 1 % 
isoflurane in 0.5 l/min O2. Once the skull was exposed and 
cleaned, a hole was drilled over the appropriate coordinates 
and brain extract from P301S tau mice (P301SBe) or WT 
mice (WTBe) was infused; a third group was infused with 
sterile PBS. each mouse received two infusions into the 
left hemisphere (Supplementary Fig. 1e). The hippocam-
pus (bregma: AP −2.50, lM +2.00; dural surface: DV 
−1.80) and then the overlying cerebral cortex/white matter 
(bregma: AP −2.50, lM +2.00; dural surface: DV −0.80) 
were unilaterally infused via a 28-gauge cannula (Plastics 
One, VA, USA) attached to an infusion pump (CMA100, 
CMA, Solna, Sweden) and fluorinated ethylene propylene 
tubing. each infusion was 2.5 µl at a flow rate of 1.25 µl/
min with the cannula remaining in place for a further 
3 min before withdrawal. Following infusion the skin was 
sutured, sedation was reversed with atipamezole (Antise-
dan© 5 mg/kg s.c.) and the mice were allowed to recover 
with postoperative analgesia (rimadyl© 5 mg/kg s.c.) in 
a temperature-controlled environment prior to returning to 
their home cages. Mice were weighed and checked daily 
for 2 weeks following surgery, with access to rehydration 
sachets and food and water ad libitum.
Histology and immunohistochemistry
At specified time points, mice were terminally anaesthe-
tised and transcardially perfused with 30 ml saline, fol-
lowed by 30 ml 10 % buffered formalin. Brains were 
removed and post-fixed in 10 % buffered formalin over-
night, before being coronally dissected into three segments 
using an adult mouse brain matrix (rBM-2000C; ASI 
Instruments, MI, USA). These segments were processed 
using the Tissue TeK® VIP processor (gMI Inc, MN, USA) 
and embedded in paraffin wax. From the middle segment, 
7 μm serial sections (from bregma 1.00 to −4.50) were cut 
using rotary microtomes (HM 200 and HM 355; Thermo 
Scientific, Microm, germany) and mounted on glass slides 
(three sections per slide). Immunohistochemistry was per-
formed using the primary antibodies listed in Table 2 and 
is described in supplementary materials. gallyas silver [18] 
and thioflavin-S [40] staining were performed as previ-
ously described, with the former being counterstained with 
methyl green (Dako, Cambridgeshire, UK) and the latter 
with DAPI (Vector laboratories, CA, USA).
Neuropathological characterisation
Stained sections (3 per slide) were digitised using the 
Scanscope XT slide scanner (Aperio, CA, USA) at 20× 
magnification. Imagescope software (version 11.1.2.760; 
Aperio, CA, USA) was used to view, delineate and analyse 
digitised tissue sections. Supplementary Fig. 1 shows the 
regions of interest (rOIs) that were delineated and their 
relative coronal level. To analyse tau pathology, the num-
ber of Pg-5- or gallyas-positive neurons was manually 
counted within a delineated rOI and expressed as density 
(mm2). For some rOIs, Pg-5 immunoreactivity was quan-
tified using the positive pixel algorithm (Imagescope, ver-
sion 11.1.2.760; Aperio, CA, USA) and expressed as the 
percentage of area burden; a similar approach was used to 
quantify Iba-1-positive microglia in dentate gyrus, layer 
CA3 and layer CA1. In white matter (fornix and internal 
capsule), tau pathology was measured using a four-tier 
semi-quantitative scoring scheme ranging from absent (0) 
to severe (3). These analyses were performed blind: (1) on 
the infused and contralateral sides of each rOI and brain; 
(2) in triplicate on serial tissue sections (mean used for sta-
tistical analysis).
Biochemical analysis
A subset of P301SBe-infused mice (2.5 months post-infu-
sion) were killed by cervical dislocation followed by rapid 
removal of the brain and immediate dissection (as shown 
in Supplementary Figure 3); individual brain segments 
were snap frozen and stored at −80 °C. Tissue samples 
were homogenised in ice-cold homogenisation buffer (sup-
plementary materials) using 15 × 1 s sonication pulses. 
Following homogenisation samples were centrifuged 
at 13,000g for 10 min at 4 °C to generate the low-speed 
fractions (lS). Protein-normalised lS fraction was further 
centrifuged at 100,000g for 30 min at 4 °C to separate the 
soluble (S1, supernatant) and insoluble (P1, pellet) frac-
tion. The P1 pellets were washed and probe sonicated in 
Table 2  Antibodies used for 
immunohistochemistry
Antibody epitope Species Dilution Source
Pg5 pSer409 Mouse 1:8,000 Kind gift from Peter Davies
MC1 Conformation dependent Mouse 1:32,000 Kind gift from Peter Davies
AT8 pSer202 and pThr205 Mouse 1:2,000 Innogenetics
Tg3 pThr231 and conformation dependent Mouse 1:3,000 Kind gift from Peter Davies
IBA-1 Ionised calcium binding adaptor 1 rabbit 1:6,000 Wako Chemicals
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50 mM Tris pH 7.4. Optimised AlphaScreen assays were 
performed using tau-specific antibodies as per manufactur-
er’s instructions (see supplementary materials) and Western 
blotting was preformed as previously described [7].
Statistical analysis
Quantitative data were analysed using Student’s t test for 
pairwise comparisons and one-way ANOVA, followed by 
either Bonferroni’s or Dunnett’s post hoc tests for group-
wise comparisons. Semi-quantitative data were analysed 
using Mann–Whitney test for pairwise comparisons and 
Kruskal–Wallis test, followed by Dunn’s post hoc test for 
groupwise comparisons. Correlation analyses were per-
formed using Spearman’s rank correlation coefficient. 
graphPad Prism 5 (version 5.04; graphPad software Inc., 
CA, USA) was used to perform statistical tests and to pro-
duce graphs, which display mean values ± SeM. Statistical 
significance was set at P < 0.05, with a trend towards sig-
nificance defined as P = 0.05–0.08.
Results
Induction of severe tau pathology in the hippocampus 
of P301S mice infused with P301SBe
examination at the infusion coordinates 2.5 months post-
infusion revealed striking Pg-5-positive tau pathology in 
the hippocampus of P301SBe mice, whereas such pathol-
ogy was only sparse in age-matched controls (infused 
with either WTBe or PBS) (Fig. 1a). Tau pathology in the 
hippocampus of P301SBe mice was severe on the infused 
side, but also spread to the contralateral side, consistent 
with propagation. Tau pathology was limited to neurons 
and glial tau pathology was not observed. Neurons in all 
hippocampal subregions were affected, but tau pathol-
ogy was particularly severe in the dentate gyrus and the 
proximal two-thirds of layers CA3 and CA1. Quantifica-
tion of Pg-5-positive neurons in the hippocampus (Sup-
plementary Fig. 1) of P301SBe-, WTBe- and PBS-infused 
mice 2.5 months post-infusion confirmed these observa-
tions (Fig. 1b). The density of Pg-5-positive inclusions was 
significantly greater in the infused and contralateral hip-
pocampi of P301SBe mice than in WTBe or PBS controls. 
In mice infused with P301SBe, the infused hippocampus had 
significantly more inclusions than the contralateral hip-
pocampus, whereas no such differences were detected in 
the WTBe or PBS groups. A similar analysis of hippocam-
pal subregions (Supplementary Fig. 2) and biochemi-
cal analysis of tau in the hippocampus of P301SBe-infused 
mice (Supplementary Fig. 3) was consistent with the above 
results. Tau-positive neuronal inclusions in P301SBe-infused 
mice had a range of distinct cytoplasmic morphologies 
(globular, perinuclear or large spherical) and were often 
associated with neuropil threads. They were also strongly 
gallyas positive (Fig. 1a), indicating that tau was in a fibril-
lar conformation reminiscent of NFTs [4]; additional stain-
ing characteristics are shown in Fig. 1c. In contrast, tau-
positive inclusions in age-matched controls (infused with 
either WTBe or PBS) were mainly diffuse, associated with 
limited neuropil threads and only weakly gallyas positive 
(data not shown); these features are consistent with pre-
tangles [4].
Progressive and stereotypical accumulation of tau 
inclusions in the hippocampus of P301SBe mice
The temporal profile of P301SBe-induced tau propagation was 
examined in the ipsilateral and contralateral hippocampi of 
P301SBe mice. Qualitative observations are shown in Fig. 2a, 
whereas quantitative changes are summarised in Fig. 2b, c. 
1 day post-infusion: No Pg-5 immunoreactivity or gallyas 
staining was observed, but disruption of layer CA1 and the 
dentate gyrus was visible (asterisk in Fig. 2a); these changes 
were found in both P301SBe and control mice. 2 weeks post-
infusion: Numerous Pg-5-positive neuronal inclusions 
were detected in the infused hippocampus, with a small 
proportion being weakly gallyas positive. Neuropil thread 
and contralateral tau pathology was limited. 1 month post-
infusion: Compared to the 2 week time point, tau pathol-
ogy was more severe in the infused hippocampus; it was 
also present (though milder) in the contralateral hippocam-
pus. On the infused side, Pg-5-positive inclusions occupied 
more of the cell soma and were accompanied by neuropil 
Fig. 1  Characterisation of P301SBe-induced hippocampal tau pathol-
ogy. a At 2.5 months post-infusion, Pg-5 immunohistochemistry 
identified severe neuronal tau pathology in the hippocampus (den-
tate gyrus, CA3 and CA1) of mice infused with P301SBe, whereas 
age-matched controls infused with either WTBe or PBS showed only 
sparse tau pathology. Neuronal tau pathology in P301SBe mice was: 
(1) accompanied by neuropil threads, (2) more severe on the infused 
than the contralateral side and (3) gallyas silver positive. b Quantifi-
cation of Pg-5-positive neurons in the infused (solid shapes) and con-
tralateral (empty shapes) hippocampi showed significant (P < 0.05) 
differences between P301SBe- (red) and WTBe- (blue) or PBS- (green) 
infused mice; in addition, the infused and contralateral hippocampi 
of P301SBe mice showed a significant difference. c At this time-point, 
Pg-5-positive tau pathology could also be detected by anti-tau anti-
bodies AT8 (recognising tau phosphorylated at Ser202/Thr205), MC1 
(conformation-dependent tau epitope) and Tg3 (phosphorylation of 
tau at Thr231 and conformation-dependent), with staining for the lat-
ter being more restricted. Confocal microscopy showed that a small 
subset of neuronal inclusions was Thioflavin-S-positive with limited 
neuropil thread staining (white arrows); such inclusions were absent 
in age-matched control mice (data not shown). Statistics: groupwise 
comparison, one-way ANOVA with Bonferroni’s post hoc test; ****, 
P < 0.0001. BE brain extract, PBS phosphate-buffered saline, WT 
wild type. Scale bars: a, 200 µm; b, 50 µm
▸
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threads. A greater proportion of neuronal inclusions were 
gallyas positive. The contralateral hippocampus was similar 
to infused side at 2 weeks post-infusion, with the exception 
that the dentate gyrus was relatively spared. 2 months post-
infusion: There was no substantial increase in the number 
of tau inclusions. Most inclusions on the infused side were 
intensely Pg-5 positive, occupied the whole cell soma and 
were associated with extensive neuropil threads. Similar 
changes were also found on the contralateral side, albeit in 
milder form, and the dentate gyrus was now also affected. 
2.5 months post-infusion: Tau pathology was most severe at 
this stage (Fig. 1). Most Pg-5-positive inclusions were also 
gallyas positive, suggesting a predominance of NFTs. Con-
sistent with these qualitative observations, quantification of 
Pg-5-positive neurons in the infused and contralateral hip-
pocampi of P301SBe mice showed a time-dependent increase 
672 Acta Neuropathol (2014) 127:667–683
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(Fig. 2b). The number of gallyas-positive neurons when 
expressed as a percentage of Pg-5 positive neurons (Fig. 2c) 
also demonstrated a time-dependent maturation from silver-
negative pre-tangles into predominately silver-positive NFTs 
in P301SBe mice [4]; see Fig. 2c and supplementary materials 
for further details.
These findings demonstrate that tau pathology in P301SBe 
mice 1) spread intracellularly (from the nerve cell soma 
to nerve cell processes), 2) spread anatomically (from the 
infused to the contralateral hippocampus) and 3) matured 
into silver-positive NFTs [4], all of which occurred in a ste-
reotypical and time-dependent fashion.
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Anatomical spread of P301SBe-associated tau pathology is 
related to connectivity, not proximity
The hippocampal formation is made up of the dentate 
gyrus, layers CA4, CA3, CA2 and CA1, subiculum, pre-
subiculum, parasubiculum and entorhinal cortex and rep-
resents a synaptic network that allows the predominately 
unidirectional passage of information [2]. To test the 
hypothesis that tau spread is related to synaptic connec-
tivity [9, 12, 26, 33], tau pathology was analysed in brain 
nuclei with and without strong synaptic connections to the 
hippocampus. See [2, 36] for details on the connectivity of 
nuclei selected for analysis. The results of this analysis are 
summarised in Table 3 and selected examples are shown 
in Fig. 3; analysis data for individual regions are shown in 
supplementary materials.
Spread of tau pathology within the hippocampal formation
The subiculum is one of the major sources of efferent pro-
jections from the hippocampal formation and is heavily 
innervated by layer CA1 and the entorhinal cortex. exami-
nation of the dorsal subiculum (Bregma −2.50) showed 
strong evidence of propagation in P301SBe mice, whereas 
control mice showed only sparse pathology (Fig. 3b). 
evidence of tau pathology was observed even at 2 weeks 
post-infusion, suggesting that it was an early feature (Sup-
plementary Fig. 4), whereas spread to the contralateral side 
first appeared at 2 months post-infusion (data not shown). 
Similar to the subiculum, the pre- and para-subiculum 
(Fig. 3c) also showed evidence of tau propagation, despite 
being posterior to the infusion site (Bregma −4.50). These 
regions receive inputs from the subiculum.
Spread of tau pathology to extrahippocampal nuclei
Tau pathology was observed in many nuclei outside the 
hippocampal formation. Some, like the retrosplenial cortex 
(rSC; Fig. 3a), were severely affected and showed pathol-
ogy as early as 2 weeks post-infusion (Supplementary 
Fig. 4), which increased in a time-dependent manner. like 
the subiculum, the rSC is relatively close to the site of infu-
sion (Bregma −2.50) and receives strong synaptic input 
from the hippocampal (CA1 and subiculum) and para-hip-
pocampal (pre- and post-subiculum) regions. The nucleus 
accumbens (bregma 1.00) and the anterior thalamic nuclear 
complex (bregma −1.00) are also synaptically connected 
to the hippocampal region. The former receives strong and 
unidirectional synaptic input from the subiculum, whereas 
the anterodorsal (ADthalamus) and anteroventral (AVthala-
mus) nuclei of the latter are reciprocally interconnected with 
the pre-subiculum. Despite being located anteriorly to the 
infusion site, these nuclei also showed a pattern of pathol-
ogy that was consistent with tau propagation (Fig. 3g–i). 
evidence of propagation was not as obvious as that seen in 
the rSC, with only the infused side showing propagation to 
the nucleus accumbens (Fig. 3i) and ADthalamus (Fig. 3g) 
of P301SBe mice 2.5 months post-infusion.
Bilateral spread of tau pathology
The lateral septal nucleus (lSN) receives unidirectional, 
bilateral projections from the hippocampal formation, specif-
ically CA3, CA1 and subiculum, through the fimbria–fornix; 
this is a prominent connection, as all CA3 and CA1 neu-
rons project to the lSN. like other synaptically connected 
regions showing evidence of propagation, the lSN also con-
tained tau pathology despite being anterior (bregma 0.00) to 
the infusion site. In contrast to regions where the infused side 
Fig. 2  Time-dependent progression of P301SBe-induced hippocam-
pal tau pathology. a representative images showing Pg-5-posi-
tive tau pathology in the hippocampus (bregma −2.50) of human 
P301S tau transgenic mice 1 day, 2 weeks, 1 month, 2 months and 
2.5 months after the infusion with P301SBe, compared to P301S tau 
mice 2.5 months after the infusion with WTBe/PBS. Insets show Pg-5 
immunohistochemistry and gallyas silver staining in the CA1 region 
(performed on adjacent serial sections); those on the right show the 
infused side and those on the left the contralateral side. Tau pathol-
ogy was absent at 1 day post-infusion, but mild infusion-related tis-
sue damage was visible on the infused side (indicated by asterisk). 
From 2 weeks post-infusion, Pg-5-positive tau pathology increased 
in a time-dependent manner on the infused side; neuronal inclusions 
became more strongly Pg-5 positive, were associated with neuro-
pil threads and became increasingly gallyas silver positive. Simi-
lar pathological changes occurred on the contralateral side 1 month 
post-infusion, where the pathology was comparatively less severe. In 
contrast, tau pathology was only sparse in the infused and contralat-
eral hippocampus of WTBe mice, even 2.5 months post-infusion. b 
The density of Pg-5-positive neurons in the hippocampus showed an 
age-associated increase on the infused and contralateral sides. From 
2 weeks post-infusion, the density of Pg-5-positive neurons was sig-
nificantly (P < 0.05) increased in the infused hippocampus of P301SBe 
mice when compared with WTBe/PBS-infused mice 2.5 months post-
infusion; similar results were obtained on the contralateral side, but 
only at 2 months post-infusion. c To investigate the relative propor-
tion of Pg-5-positive, silver-negative tau inclusions (pre-tangles) ver-
sus Pg-5-positive and silver-positive inclusions (NFTs), the number 
of gallyas-positive neurons in the CA1 region was expressed as the 
percentage of the number of Pg-5-positive neurons quantified in 
the same region, but on an adjacent serial section. At 2 weeks post-
infusion, the majority of tau inclusions in P301SBe-infused mice were 
pre-tangles, whereas by 2.5 months both the infused and contralateral 
hippocampi contained predominantly NFTs. In contrast, pre-tangles 
predominated in PBS-infused mice, even 2.5 months post-infusion. 
Comparison of P301SBe and PBS groups at 2.5 months post-infu-
sion showed a significant increase in NFTs in the former. Statis-
tics: groupwise comparison, one-way ANOVA with Dunnett’s post 
hoc test (b) and one-way ANOVA with Bonferroni’s post hoc test 
(c); pairwise comparison, Student’s t test (c). BE brain extract, WT 
wild type, d day, w weeks, m month; *, P < 0.05; **, P < 0.01; ***, 
P < 0.001; ****, P < 0.0001. Scale bars: a, 1 mm; insets, 100 µm
◂
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was more severely affected than the contralateral side, the 
severity of pathology in the lSN was similar on both sides 
(Fig. 3f, n). A small subset of P301SBe mice showed mild tau 
pathology in the lSN at 2 weeks post-infusion, but only on 
the contralateral side, whereas more substantial pathology 
was observed on both sides at 1 month post-infusion (data 
not shown). What distinguishes the lSN from other propaga-
tion-associated nuclei is that the projection from layer CA3 
is bilateral, which may explain the tau spread to both sides.
Anterograde and retrograde spread of tau pathology
The medial and lateral mammillary nuclei (mlMN) receive 
strong unidirectional, bilateral inputs from the subicu-
lum and para-hippocampus through the fimbria–fornix. 
As these connections are not reciprocal, return projections 
from the mammillary body to the subiculum (and the den-
tate gyrus) originate from the supramammillary nucleus 
(suMN). Despite being approximately 5 mm from the site 
of infusion, both regions showed statistically significant 
evidence of tau pathology (Fig. 3d, e), which was par-
ticularly prominent in the mlMN (Fig. 3o). Spread from 
the hippocampal formation to the mlMN is an example of 
anterograde spread, whereas that to the suMN constitutes 
retrograde spread. Consistent with the bilateral arrange-
ment of these connections, the severity of tau pathology on 
the infused and contralateral sides of P301SBe mice was not 
significantly different. Furthermore, evidence of propaga-
tion was observed as early as 2 weeks post-infusion (Sup-
plementary Fig. 5), suggesting that the anterograde and ret-
rograde spread of tau pathology occurred relatively early.
Nuclei with no evidence of propagation-associated tau 
pathology
The lateral geniculate nucleus (lgN; Bregma −2.50) 
receives inputs from the retina and projects to the visual 
cortex via the internal capsule. Although it is not directly 
Fig. 2  continued
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connected to the hippocampal formation, it is in close prox-
imity to the dentate gyrus, layer CA3 and the lower infu-
sion coordinate (Supplementary Fig. 1). Despite this close 
proximity, the lgN did not show evidence of tau propaga-
tion (Fig. 3j); however, it is prone to P301SBe-associated tau 
pathology when targeted by a more ventral infusion coordi-
nate (dural surface: DV −2.80; data not shown). Other brain 
regions, such as the ventrolateral thalamic nucleus (Vlthala-
mus; bregma −1.00), the striatum (bregma 1.00) and the glo-
bus pallidus (bregma −1.00), are not directly connected to 
the hippocampal formation and did not show evidence of tau 
propagation in P301SBe mice. Analysis of tau propagation in 
the cerebral cortex can be found in supplementary materials.
relationship between connectivity and tau propagation
It is of note that all brain regions (Table 3) that showed evi-
dence of tau propagation are directly connected to the hip-
pocampus (dentate gyrus, CA3 or CA1) and/or the wider 
hippocampal formation (including subiculum and para-
hippocampal region). Those that did not show evidence of 
tau propagation, irrespective of relative proximity, are not 
directly linked to the hippocampal formation. Tau spread to 
distal sites (e.g. mlMN) occurred relatively quickly, in both 
a retrograde (suMN) and anterograde (mlMN) fashion.
Tau pathology in white matter that connects the 
hippocampal formation to regions showing evidence of tau 
propagation
The hippocampal formation is associated with three major 
white matter tracts: the angular bundle, the hippocampal 
commissure and the fimbria–fornix [2]. The hippocam-
pal commissure represents the connection between right 
and left hippocampi, while the fimbria–fornix connects 
the hippocampal formation with the basal forebrain (e.g. 
lSN) and hypothalamic (e.g. mlMN and suMN) regions. 
As these regions (along with the hippocampal formation) 
Table 3  Tau propagation to brain regions distal to the infusion site
evidence of tau propagation was analysed in various brains regions of P301S Be-infused mice at 2.5 months post-infusion (see Supplementary 
materials for analysis data). Tau propagation was defined as a region showing significantly more tau pathology in P301SBe mice compared to 
PBS controls (highlighted in italic); those that did not are highlighted in bold. This table also shows the orientation (relative to infusion target), 
the bregma level and the connectivity of each region of interest. Tau propagation occurred in regions with direct connections (highlighted in 
bold) with the hippocampal formation and not to those without such connections (highlighted in italic); relative proximity to the site of infusion 
(bregma −2.50) did not influence tau propagation
BE brain extract, A/P anterior/posterior, Sup supplementary




Direct connection to  
hippocampal formation?
evidence of tau propagation  
inP301SBe mice?
Fig.
Para-hippocampal region Posterior −4.50 Yes Yes 3c
Dentate gyrus (posterior) Posterior −4.00 Yes Yes –
retrosplenial cortex Dorsal −2.50 Yes Yes 3a, 3m
Dorsolateral cortex Dorsal −2.50 No No –
Dorsal subiculum Medial −2.50 Yes Yes 3b
Hippocampus region Target −2.50 Yes Yes 1b
Dentate gyrus Target −2.50 Yes Yes Sup. 2
CA3 Target −2.50 Yes Yes Sup. 2
CA1 Target −2.50 Yes Yes Sup. 2
Medial–lateral mammillary nucleusVentral −2.50 Yes Yes 3d, 3o
Supramammillary nucleus Ventral −2.50 Yes Yes 3e
Ventrolateral cortex Ventral −2.50 Yes Yes –
lateral geniculate nucleus Ventral −2.50 No No 3j
Anterioventral thalamus Anterior −1.00 Yes Yes 3h
Dentate gyrus (anterior) Anterior −1.00 Yes Yes –
CA3 (anterior) Anterior −1.00 Yes Yes –
Anteriodorsal thalamus Anterior −1.00 Yes Yes 3g
globus pallidus Anterior −1.00 No No 3k
Ventrolateral thalamus Anterior −1.00 No No –
lateral septal nucleus (dorsal) Anterior 0.00 Yes Yes 3f, 3n
Nucleus accumbens Anterior 1.00 Yes Yes 3i
Caudate/putamen Anterior 1.00 No No 3l
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Fig. 3  Propagation of tau 
pathology to brain regions distal 
to the infusion site. The density 
of Pg-5-positive neurons or the 
area occupied by Pg-5-pos-
itive immunoreactivity (tau 
burden;  % area) was quanti-
fied in discrete brain regions 
distal to the site of infusion. 
This analysis was conducted in 
P301SBe (red) and PBS (green) 
mice 2.5 months post-infusion, 
both on the infused (solid 
bars) and the contralateral 
(checked bars) sides. Statistical 
analysis identified regions with 
significantly more tau pathol-
ogy in P301SBe mice than in 
PBS controls. The results of 
this analysis are summarised in 
Table 3. Tau propagation was 
detected in numerous distal sites 
(a–i), all of which have strong 
synaptic connections with 
the hippocampal formation. 
regions not directly connected 
to the hippocampal formation 
(j–l) showed no evidence of tau 
propagation. representative 
images showing Pg-5 staining 
in retrosplenial cortex (m), 
lateral septal nucleus (n) and 
medial/lateral mammillary 
nucleus (o) serve to illustrate 
the severity and distribution of 
tau pathology in P301SBe and 
PBS mice. RSC retrosplenial 
cortex, mlMN medial/lateral 
mammillary nucleus, suMN 
supramammillary nucleus, LSN 
lateral septal nucleus, ADthala-
mus anterodorsal thalamus, 
AVthalamus anteroventral thala-
mus, LGN lateral geniculate 
nucleus, BE brain extract, PBS 
phosphate-buffered saline. Scale 
bars: 150 µm
677Acta Neuropathol (2014) 127:667–683 
1 3
showed strong evidence of tau propagation in P301SBe 
mice, tau pathology was analysed in dorsal and ventral for-
nix (Fig. 4a; inset). The internal capsule was also analysed 
as it is not directly connected to the hippocampal formation 
or regions that showed evidence of tau propagation.
At 2.5 months post-infusion, the dorsal and ventral for-
nix of P301SBe mice contained numerous Pg-5-positive 
‘dot-like’ structures (Fig. 4). These were more numerous in 
the infused half compared to the contralateral half and were 
relatively infrequent in age-matched controls. They were 
absent at 1 day post-infusion (data not shown) and were 
numerous at 2 weeks, when they were largely confined to 
the infused side of the dorsal and ventral fornix (Fig. 4). 
Semi-quantitative scoring of Pg-5-positive tau pathology 
confirmed these qualitative observations (Fig. 4b, c). Addi-
tionally, the severity of fornix tau pathology on the con-
tralateral side of P301SBe mice showed an increase between 
2 weeks and 2.5 months, whereas it remained relatively 
Fig. 4  P301SBe-induced tau pathology in white matter tracts. a The 
fornix (red) is a white matter tract that projects from the hippocam-
pal formation (orange) to the basal forebrain structures, including the 
mammillary nucleus (green), both of which contain P301SBe-induced 
tau pathology (Table 3; Fig. 3). representative images of the dorsal 
and ventral aspects of the fornix (bregma −1.00; corresponding to 
the red dotted line) showed Pg-5-positive dot-like structures (insets) 
that were more numerous in P301SBe mice than in controls. The mor-
phology and location of these dot-like structures are compatible with 
tau aggregates in neuronal axons (cut in cross section; inset). Semi-
quantitative scoring in the dorsal (b) and ventral fornix (c) confirmed 
that tau pathology was more severe (P < 0.05) on the infused side 
of P301SBe mice at 2 weeks (0.5 months) and 2.5 months post-infu-
sion when compared with controls. On the contralateral side, there 
was an increase in tau pathology between 2 weeks and 2.5 months 
in P301SBe mice (significant for the ventral fornix). At both 2 weeks 
and 2.5 months, tau pathology was significantly more severe on the 
infused side of P301SBe mice compared to the contralateral side. 
A similar analysis of the internal capsule (d) did not identify any 
P301SBe-induced changes in tau pathology, although there was a 
mild but significant increase between 2 weeks and 2.5 months post-
infusion. Statistics: groupwise comparison, Kruskal–Wallis test with 
Dunn’s post hoc test; Pairwise comparison, Mann–Whitney test; ***, 
P < 0.001; **, P < 0.01; *, P < 0.05; #, P > 0.05 and ≤0.08 (trend). d 
dorsal, l lateral, v ventral, r rostal, c caudal, INF relative coronal level 
of the infusion site, BE brain extract, PBS, phosphate-buffered saline. 
Scale bars: 100 µm
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unchanged on the infused side. In contrast, the internal cap-
sule was unaffected 2 weeks post-infusion and showed a 
mild, but significant increase in tau pathology at 2.5 months 
for both P301SBe mice and control mice, with no difference 
between the infused and contralateral sides (Fig. 4d). The 
morphology and location of these ‘dot-like’ structures is 
consistent with tau aggregates in neuronal axons (observed 
in cross-section) [32]. Axonal localisation of these white 
matter tau aggregates in P301SBe mice was more readily 
visible in the ventral hippocampal commissure (observed 
in longitudinal section) where tau pathology had a simi-
lar severity to that observed in the fornix (Supplementary 
Fig. 5). These findings suggest that the fornix progressively 
develops axonal tau pathology in response to the unilateral 
infusion of P301SBe into the hippocampus, consistent with 
tau propagation, whereas the internal capsule does not.
No overt neurodegeneration associated 
with P301SBe-induced hippocampal tau pathology
Despite the severity of tau pathology in P301SBe-infused 
mice, there was no obvious nerve cell loss. A small subset 
of mice showed acute neuronal loss in the dentate gyrus and 
layer CA1 (Fig. 2a), but this was not specific to any of the 
treatment groups and was observed even 1 day post-infu-
sion (data not shown), suggesting that it was unrelated to 
the accumulation of tau pathology and more likely associ-
ated with the mechanical nature of the infusion procedure. 
Analysis of Iba-1 staining for microgliosis was consistent 
with this notion (Supplementary materials). This analy-
sis also identified a subtle increase in microgliosis in the 
oldest P301SBe-infused mice (Supplementary Fig. 6) which 
might be indicative of an early inflammatory response to 
neurodegeneration.
Discussion
We adapted the human mutant P301S tau transgenic mouse 
line to develop a novel in vivo model of tau propagation, 
termed P301S-TP. In our model, P301SBe-induced tau 
pathology formed first in the hippocampus on the infused 
side, from where it spread to the contralateral hippocampus 
and to distal nuclei that are synaptically connected to the 
hippocampal formation. White matter tracts connecting the 
hippocampal formation to these distal nuclei also showed 
evidence of P301SBe-induced tau pathology.
P301S-TP as a rapid and robust model of tau propagation
The lack of significant tau pathology in the hippocampus 
of P301S tau mice infused with PBS or WTBe indicates that 
this region is relatively spared at 4.5 months of age and that 
the induction and robust accumulation of tau pathology in 
P301S-TP mice is attributable to the infusion of P301SBe. 
The absence of tau pathology at 1 day shows that inclu-
sions were not simply transferred from symptomatic to 
asymptomatic mice, but rather that the resulting intraneu-
ronal deposits accumulated over time. Mild tissue disrup-
tion and associated microgliosis were observed 1 day post-
infusion in both P301SBe- and PBS-infused mice resulting 
from the needle tracks; however, this had no obvious effect 
on the induction of tau inclusions, since no differences 
were observed between infused and contralateral sides. It 
is unlike a recent study, which reported the rapid accumu-
lation of oligomeric and phosphorylated tau in response to 
traumatic brain injury [24].
Temporal analysis of the hippocampus showed that the 
induction, maturation and spread of P301SBe-associated tau 
pathology occurred in a stereotypical and time-dependent 
manner resembling that in human brain, which underlies 
Braaks’ NFT staging scheme [5]. We saw induction of hip-
pocampal tau pathology within 2 weeks post-infusion, its 
contralateral spread within 1 month and a predominance 
of NFTs after 1 month, allowing us to effectively stage the 
progression of tau pathology in this novel mouse model. 
A transition from hyperphosphorylated, silver-negative to 
hyperphosphorylated, silver-positive tau inclusions in the 
P301S-TP model is also similar to the evolution of NFTs 
described in AD [3, 4]. Braak and colleagues described 
five groups based on hyperphosphorylated tau (antibody 
AT8) and gallyas silver staining: (1) pre-tangles (only AT8 
positive); (2) beginning of NFTs (AT8- and weakly gallyas 
positive); (3) ‘classic’ NFTs (AT8- and gallyas positive); 
(4) early ghost tangle (weakly AT8- and gallyas posi-
tive); (5) extracellular ‘ghost tangle’ (weakly gallyas posi-
tive) [4]. The majority of inclusions in the hippocampus of 
P301S-TP mice at 2 weeks post-infusion were pre-tangles 
and at 2.5 months NFTs. extracellular tau inclusions were 
not observed, consistent with the lack of overt nerve cell 
loss. Similarly, only a small subset of Pg-5-positive inclu-
sions was thioflavin-S- or Tg3 positive, which are mark-
ers of mature NFTs [26]. It is possible that further ageing 
of P301S-TP might increase the frequency of mature NFTs 
and result in neuronal loss; however, since P301S tau mice 
develop a severe paraparesis by 5–5.5 months of age [1], 
we did not age the mice beyond 4.5 months.
The first in vivo model of tau propagation showed a simi-
lar induction of tau pathology. Clavaguera et al. [9] used an 
identical P301SBe preparation composed of hyperphosphoryl-
ated, filamentous tau and infused it into the AlZ17 line that 
overexpresses wild-type 4r human tau. Immunodepletion of 
tau from P301SBe inhibited the induction and accumulation 
of pathology, indicating that its presence was essential for 
propagation. They also showed that overexpression of wild-
type human tau was necessary for significant accumulation 
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of pathology and that it formed the P301SBe-induced tau 
inclusions [9]. In the present study we observed a more rapid 
and robust induction of tau pathology than when AlZ17 
was used as the recipient mouse line [9]. The AlZ17 model 
of propagation showed nerve cell body inclusions after 
15 months and only modest contralateral spread even after 
18 months [9]. Our P301S-TP model, using an identical 
infusion methodology (i.e. infusion preparation, coordinates, 
volume and flow rate), developed tau inclusions as early as 
2 weeks post-infusion and showed contralateral hippocam-
pal spread after 1 month. As the experimental methodolo-
gies were matched, the difference between models is likely 
to be related to the overexpression of human mutant P301S 
tau, which is more aggregation prone than WT human tau 
[21]. The concentration of total tau protein in P301SBe, which 
was threefold higher than WTBe (supplementary materials), 
is unlikely to be the critical factor for initiating tau propaga-
tion in our model as it is also seen (to a lesser degree) when 
P301SBe is diluted tenfold (data not shown). endogenously 
expressed murine tau has been shown to accumulate in 
propagation-associated inclusions [8, 9, 12, 26] and is likely 
to be incorporated into inclusions formed in our P301S-
TP model, although this was not tested. Collectively, these 
results are consistent with in vitro studies showing that syn-
thetic tau fibrils recruited and converted endogenous soluble 
tau species into fibrillar aggregates [17, 23, 27, 49]. These 
features are also characteristic of other amyloidogenic pro-
teins, such as α-synuclein, amyloid β and prion protein [19, 
43]. Although the characteristics of tau that enabled seeding 
and templating are still unknown, it has been shown that tau 
extracts from human tauopathies [8, 30] and synthetic tau 
fibrils can induce tau pathology in vivo [10, 26].
Tau propagation is related to synaptic connectivity, not 
spatial proximity
Other models of tau propagation used either a tau infu-
sion paradigm similar to the one used here [9, 26, 30] or 
the region-specific expression of human mutant tau [12, 
33]. Both approaches have suggested that tau pathology 
can spread to distal brain regions that are synaptically con-
nected to the area where tau pathology was first induced. A 
potential weakness of the region-specific expression mod-
els is the possibility of low human mutant tau expression 
in the synaptically connected regions [42]. A drawback 
of the infusion models is the possibility of aggregated tau 
diffusing from the sites of infusion, forming a proximal–
distal gradient and inducing pathology only in regions with 
a high basal expression of tau. Moreover, the connectivity 
of specific nuclei with and without propagation-associated 
pathology was not always examined or emphasised [9, 26].
Analysis of tau propagation in over 20 nuclei located 
anteriorly, posteriorly, ventrally or dorsally to the site of 
infusion provided conclusive evidence that tau pathology 
spread only to regions that were synaptically connected 
to the site of infusion (Fig. 5). Nuclei that are not directly 
connected to the hippocampal formation did not show 
evidence of tau propagation. The lack of tau propagation 
to the lgN, a nucleus not connected but in close prox-
imity to the hippocampus, discounts the possibility of 
tau seeds simply diffusing from the infusion site to dis-
tal nuclei. The lgN forms tau inclusions when infused 
with P301SBe (data not shown). In most nuclei showing 
evidence of P301SBe-induced tau propagation, the infused 
side was more severely affected than the contralateral 
side, both of which were affected more than either side 
of WTBe- or PBS- infused mice. The lSN displayed a 
different pattern of pathology with the infused and con-
tralateral sides showing equally severe P301SBe-induced 
pathology. This bilateral spread of tau pathology is likely 
to be a reflection of the strong bilateral and unidirectional 
inputs from one side of the hippocampus to both sides 
of the lSN [2]. The correlation between the pattern of 
spread and the synaptic connectivity of the lSN lends 
further support to a mechanism of spread related to syn-
aptic connectivity and not proximity. The lack of prop-
agation-related tau pathology in the dorsolateral cortex, 
which is close in proximity to the dorsal infusion coordi-
nate and contains the primary visual cortex (Fig. 5), sug-
gests that the hippocampus is the major mediator of tau 
spread in this model.
A model of tau propagation, which used microfluidic 
chambers to separate somatodendritic and axonal compart-
ments, has shown that aggregated tau can be internalised 
by both compartments and transported along the axon in 
either the anterograde or the retrograde direction [49]. Most 
nuclei showing evidence of tau propagation in the present 
study were hippocampal efferents and therefore reflected 
an anterograde axonal spread. For example, the mlMN 
receives strong, unidirectional and bilateral efferent con-
nections from the hippocampal formation [2] and shows 
evidence of bilateral P301SBe-induced tau pathology. The 
hippocampal region receives afferent axons from neurons 
in the suMN, which also shows evidence of tau propaga-
tion [2]. Consistent with the in vitro model [49], this is 
likely to be an in vivo example of retrograde spread, where 
tau aggregates are internalised by the axonal terminals of 
suMN neurons and transported along their axons in retro-
grade fashion to seed more tau aggregation in the distally 
located somatodendritic compartment.
The concept of anterograde and retrograde transport of 
assembled tau was further supported by the identification 
of tau aggregates in the fornix of P301S-TP mice, most 
likely within axons, since tau accumulation in oligoden-
droglia was not observed. This stands in marked contrast 
to the AlZ17 line, where numerous coiled bodies were 
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present following the infusion of either P301SBe or brain 
extracts from human tauopathies [8, 9]; the reason for 
this difference remains to be established. The relatively 
long distance (~5 mm) from the infusion site to the mam-
millary nucleus via the fornix and the normally tightly 
regulated movement of proteins along axons suggest that 
the transport of aggregated tau species was probably an 
active process. If the purpose of this active transport is to 
neutralise abnormal tau species in the somatodendrictic 
compartment, this raises the question why tau would be 
anterogradely transported. The abnormal conformation/
post-translational modification of tau could be a factor 
leading to its apparent mislocalisation and ability/avail-
ability to propagate from cell to cell.
Is the P301S-TP model relevant to human diseases?
It has long been thought that abnormal tau accumulates in 
a cell-autonomous manner and that its distribution reflects 
the greater vulnerability of some neuronal populations, 
possibly related to variations in tau expression. Although 
this may be true in part, the results of this study and other 
in vivo models of tau propagation [9, 12, 26, 30, 33] high-
light the ability of tau to affect whole neuronal networks 
as opposed to isolated neurons/nuclei. There is growing 
evidence that network-dependent or ‘trans-synaptic’ spread 
of tau pathology also occurs in human tauopathies. Firstly, 
Braaks’ staging suggests that tau pathology occurs early 
in the transentorhinal region, from where it spreads to the 
Fig. 5  Tau propagation is related to connectivity, and not proximity. 
Schematic of the mouse brain at two sagittal levels (lateral: 2.04 and 
0.60) shows the structural relationship between nuclei with (red) and 
without (green) evidence of tau propagation. The former are synapti-
cally connected to neurons in the hippocampus (dark red), the target 
of the P301SBe infusion (purple dots). Nuclei located anteriorly and 
ventrally are connected to the hippocampus through the fimbria–
fornix (FF), which also showed evidence of tau propagation. The lat-
eral geniculate nucleus (lg), which was proximal to the site of infu-
sion, did not exhibit propagation and was not synaptically connected 
to the hippocampus, nor are nuclei associated with the striatonigral 
system that are interconnected through the internal capsule. This dis-
tribution suggests that tau spreads to regions synaptically connected 
to the infusion site and not necessarily to regions in close proximity. 
Only specific nuclei were analysed for evidence of tau propagation 
(Table 3) and the sagittal levels were selected for illustrative pur-
poses only. Grey dotted lines indicate anterior/posterior bregma lev-
els in which nuclei were sampled (Supplementary Fig. 1). AT anterior 
thalamus, CA, CA1-3, CC corpus callosum, CP caudate/putamen, DG 
dentate gyrus, FF fimbria/fornix, FI fimbria, GP globus pallidus, HP 
hippocampus, IC internal capsule, LG lateral geniculate nucleus, LSN 
lateral septal nucleus, MN mammillary nucleus, NAc nucleus accum-
bens, RSC retrosplenial cortex, Sub subiculum, VC visual cortex, VT 
ventral thalamus
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hippocampus and the neocortex [5]. The perforant path-
way is likely to facilitate this apparent spread, as it origi-
nates from the entorhinal cortex and is the major source of 
input for the hippocampal formation [2], a view supported 
by the expression models of tau propagation [12, 33]. Sec-
ondly, the nuclei that are affected in human tauopathies do 
not appear to be random, but form part of large-scale neu-
ronal networks. Network-dependent spread could help to 
explain the selective vulnerability of the limbic system in 
AD or the severe pallido-nigro-luysial involvement in PSP 
and CBD [13, 37, 41]. Finally, network-dependent spread 
could account for heterogeneity within a distinct diagnos-
tic tauopathy. There is considerable homogeneity that ena-
bles the identification of tauopathies (e.g. morphology of 
tau inclusions), but there is also a degree of heterogeneity 
unrelated to disease severity, which has led to the defini-
tion of clinicopathological variants of disease [14, 28, 34]. 
Thus, posterior cortical atrophy is an atypical variant of AD 
characterised by severe NFT pathology in the occipitopari-
etal cortex, with relative sparing of the hippocampus [46]. 
Network-dependent spread could explain this, if the initial 
tau aggregation was a stochastic event that was followed by 
deterministic spreading dependent on network connectiv-
ity. This concept could be put to the test in the P301S-TP 
model using different infusion coordinates.
Together with the present work, in vivo and human stud-
ies highlight the potential importance of the white mat-
ter in facilitating the spread of tau pathology. It is of note 
that the white matter is severely affected in PSP and CBD 
[13], and has been previously implicated in the spread of 
tau pathology in AD and other human tauopathies [29, 37, 
41]. Manipulation of these discrete functional connections 
in the P301S-TP model through white matter transections, 
grey matter lesions or pharmacological manipulation is 
likely to shed light on the mechanism(s) of network spread, 
i.e. it could be used to investigate if spread is truly “trans-
synaptic” [12, 33].
Downstream consequences of tau propagation
In contrast to the parent line, which develops nerve cell 
loss in the anterior horn of the spinal cord and other 
parts of the central nervous system, P301S-TP mice did 
not develop frank neurodegeneration, consistent with 
other infusion models of tau propagation [9, 26, 30]. 
With tau pathology being minimal in the hippocampus 
(at 4.5 months) and severe in the spinal cord of the par-
ent line [1], the disparity in neurodegeneration may to 
be related to the presumed lower expression of human 
P301S tau transcripts in the hippocampus. Thus, higher 
transgene expression in the spinal cord may be required to 
drive neurodegeneration, whereas a combination of lower 
hippocampal expression and the transient nature of the 
infusion procedure may be sufficient for inclusion forma-
tion, but not toxicity. This is reminiscent of the inhibition 
of neurodegeneration after transgene suppression in con-
ditional models of tauopathy, despite the continued forma-
tion of NFTs [39]. These observations imply that propaga-
tion is necessary, but not sufficient for neurodegeneration 
and that the molecular species responsible for propagation 
and toxicity may be different [8, 11]; the relevant molecu-
lar tau species remain to be identified.
Another possibility is that hippocampal neuronal loss 
may eventually develop upon further ageing of P301S-
TP mice, as significant neuronal loss in the parent line 
was reported at 6 months. The oldest P301S-TP mice 
(4.5 months) showed subtle evidence of increased micro-
gliosis in layer CA3, a region affected early and severely 
by tau pathology and devoid of infusion-related damage. 
Increased microgliosis could be indicative of a neurodegen-
erative process, since microglia monitor the brain micro-
environment and respond to tissue injury and degeneration 
[35, 45].
Conclusion
The P301S-TP model shows rapid and robust tau pathol-
ogy, which progresses in a stereotypical and time-depend-
ent manner similar to that observed in human tauopathies. 
These characteristics make it a suitable and flexible assay 
system for the development and testing of tau-based treat-
ment strategies, with the ultimate aim of finding interven-
tion and prevention strategies for human tauopathies. The 
characterisation of pathology over time should help tai-
lor the present model to reflect pre-pathological (1 day–
2 weeks post-infusion) mild/early (2 weeks–1 month 
post-infusion) or severe/late (1–2.5 months post-infusion) 
stages of tauopathy, as it is likely that some therapeutic 
strategies will be more effective at particular stages of 
disease. The model will also help us to understand the 
mechanisms underlying network-dependent spread and 
provide answers to fundamental questions regarding the 
tau species responsible and the molecular mechanism(s) 
of tau propagation.
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